Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 4,090 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obstructive Clear all
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 17, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Interventions
Asciminib single agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Upper Airway Obstruction

NCT04322097
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Hypoglossal Nerve Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
Drug
Lead sponsor
Expedition Therapeutics, Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Northridge, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Menstrual Differences in Airway Inflammation in Asthma

NCT00584441
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

Coping Skills Training (CST) for Children With Chronic Health Conditions

NCT00359775
View directory record Official record
Conditions
Rheumatologic Conditions (JRA,Lupus), Epilepsy, Spina Bifida, Asthma
Interventions
Coping Skills Training
Behavioral
Lead sponsor
Children's Hospital and Health System Foundation, Wisconsin
Other
Eligibility
8 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity

NCT00589719
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
4 Years to 17 Years
Enrollment
964 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

NCT06529419
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo, Inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Mesa, Arizona • Huntington Beach, California • La Mesa, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT06299683
View directory record Official record
Conditions
Chronic Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Cystitis, Interstitial, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Psychosocial Treatment, Pelvic Floor Physical Therapy
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational Results available

Evaluation of VLER-Indiana Health Information Exchange Demonstration Project

NCT01446705
View directory record Official record
Conditions
Diabetes Mellitus, Asthma, Cardiovascular Diseases, Heart Failure, Osteoporosis
Interventions
Active Health Information Exchange, Non-Active Health Information exchange
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
57,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 17, 2026, 1:37 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

NCT02123966
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease
Interventions
Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational

Factors That Affect the Development of COPD Symptoms

NCT00740337
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Sleep Quality With Emerging Technologies

NCT06900530
View directory record Official record
Conditions
Snoring, Sleep Disturbances, Hypoxia, Obstructive Sleep Apnea (OSA)
Interventions
Not listed
Lead sponsor
Case Western Reserve University
Other
Eligibility
20 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Results available

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00280241
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea

NCT00672737
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Remifentanil, Cold pain threshold and tolerance, Heat pain threshold and tolerance, Polysomnography
Drug · Procedure · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

NCT06502366
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
70
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions

NCT01878929
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Allergic Conjunctivitis
Interventions
Allergen(Tree, Grass, Weeds)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

NCT03800901
View directory record Official record
Conditions
Diabetes, Hypertension, Depression, Osteoarthritis, Asthma, Pain, Heart Failure
Interventions
Continuing Medical Education, Quality IQ Patient Simulations
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Results available

Tailored Intervention to Promote Positive Airway Pressure Adherence

NCT01454830
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Patient Compliance
Interventions
Tailored, Usual care
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational

MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR

NCT06139094
View directory record Official record
Conditions
Ischemic Heart Disease, Coronary Microvascular Disease, Angina
Interventions
CardioFlux Magnetocardiography
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Gainesville, Florida • Detroit, Michigan • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 17, 2026, 1:37 PM EDT
Completed No phase listed Observational

Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.

NCT01174277
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Interventions
Collection of blood sample
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
7 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 17, 2026, 1:37 PM EDT
Active, not recruiting No phase listed Observational

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

NCT00285012
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, Varenicline Tartarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2010 · Synced Oct 17, 2026, 1:37 PM EDT